Jiangsu Hengrui Pharmaceutical Co., Ltd

Jiangsu Hengrui Pharmaceutical Co., Ltd. was founded in 1970 and listed on Shanghai Stock Exchange in 2000 with the stock code of 600276. It is a large research and production base of antineoplastic drugs and surgical drugs in China. At present, it is one of the large pharmaceutical enterprises with relatively innovative ability in China.

In 2010, the company achieved a sales revenue of 3.75 billion yuan and a profit and tax of 1.5 billion yuan, with a substantial increase in various economic indicators compared with the same period last year.

Focus on the innovation and development of anti-tumor drugs, surgical drugs, endocrine therapy drugs, cardiovascular drugs and anti infective drugs, and gradually form brand advantages. The company has an annual production capacity of 1.5 billion tablets, 100 million injections, 10 million soft bag infusion bags, 10 million bottles of oral liquid, 100 million capsules and 10 million ointments. All dosage forms of the company have passed the national GMP certification. Another four APIs have passed FDA certification. In July 2010, FDA officials of the United States went to the company to conduct the certification inspection of the preparation, which is to build a brilliant international brand of Hengrui medicine.

In the practice of market competition, we realize that competition mainly depends on innovation, especially technological innovation in key areas. To this end, Hengrui medicine has established three research centers and a clinical medicine department in the United States, Shanghai and Lianyungang, with more than 800 high-level professional and technical personnel, including nearly 500 doctors, masters and overseas returnees.

In recent years, the company has successively undertaken 4 National 863 program major science and technology special projects, 9 projects listed in the national "major new drug creation" special project, 12 national Torch Program projects, 7 national Spark Program projects and dozens of provincial science and technology research projects. The company has applied for nearly 180 invention patents, including 60 global patents (PCT patents), and 1 innovative drug irecoxib has been applied Another 8 innovative drugs are in different clinical stages, and many innovative drugs are applying for clinical application.

In order to gain the initiative in the fierce market competition, the company has established and improved a nationwide sales network system, with a sales team of more than 3000 people. It has more than ten brand products with annual sales of over 100 million yuan and more than 500 million yuan. The company also actively expands the markets of the United States, Europe, India, South America and other countries and regions, and expands export channels.

Launch more brand introductions

Brand news